Déjà vu for breast cancer two?

J Natl Cancer Inst. 2004 Apr 7;96(7):497-9. doi: 10.1093/jnci/djh119.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Age Factors
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / analysis*
  • Breast Neoplasms / chemistry*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / pathology
  • Clinical Trials as Topic
  • Disease-Free Survival
  • Estrogen Receptor Modulators / therapeutic use
  • Female
  • Humans
  • Incidence
  • Middle Aged
  • Neoplasms, Hormone-Dependent / chemistry*
  • Neoplasms, Hormone-Dependent / drug therapy
  • Neoplasms, Hormone-Dependent / pathology
  • Neoplasms, Multiple Primary / chemistry*
  • Neoplasms, Multiple Primary / prevention & control
  • Neoplasms, Second Primary / chemistry*
  • Neoplasms, Second Primary / prevention & control
  • Predictive Value of Tests
  • Receptors, Estrogen / analysis*
  • Receptors, Progesterone / analysis*
  • Retrospective Studies
  • Survival Analysis
  • Tamoxifen / therapeutic use

Substances

  • Antineoplastic Agents, Hormonal
  • Biomarkers, Tumor
  • Estrogen Receptor Modulators
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Tamoxifen